위마비 약물 시장 보고서(2026년)

Gastroparesis drugs are medications used to treat and manage gastroparesis, a disorder in which the stomach empties its contents more slowly than normal, leading to symptoms such as nausea, vomiting, and abdominal pain. These medications commonly include prokinetic agents that enhance stomach motility, antiemetic drugs to reduce nausea and vomiting, and other therapies to manage pain and related symptoms.

The primary drug types for gastroparesis include over-the-counter (OTC) drugs and prescription drugs. Over-the-counter drugs are medicines that can be obtained without a healthcare provider's prescription. These drugs are used to treat different disease types, including diabetic gastroparesis, post-surgical gastroparesis, idiopathic gastroparesis, and others, and are administered through various routes, mainly oral, injectable, and others. The drug categories include prokinetic agents, antiemetic drugs, proton pump inhibitors, and others, and they are distributed through hospitals, pharmacies, clinics, and e-commerce channels.

Tariffs have impacted the gastroparesis drugs market by increasing the cost of imported active pharmaceutical ingredients, intermediates, and formulation components used in both otc and prescription medications. These impacts have been most visible in prokinetic and antiemetic drug classes, particularly in North America and Europe where api sourcing is globally diversified. Asia-Pacific manufacturers have experienced pricing pressure due to trade-related supply dependencies. However, tariffs have encouraged domestic api production and local manufacturing of gastrointestinal drugs, supporting supply continuity and market stability.

The gastroparesis drugs market research report is one of a series of new reports from The Business Research Company that provides gastroparesis drugs market statistics, including gastroparesis drugs industry global market size, regional shares, competitors with a gastroparesis drugs market share, detailed gastroparesis drugs market segments, market trends and opportunities, and any further data you may need to thrive in the gastroparesis drugs industry. This gastroparesis drugs market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The gastroparesis drugs market size has grown strongly in recent years. It will grow from $5.7 billion in 2025 to $6.02 billion in 2026 at a compound annual growth rate (CAGR) of 5.7%. The growth in the historic period can be attributed to increasing diagnosis of diabetic gastroparesis, long-standing use of prokinetic and antiemetic drugs, growing prevalence of diabetes-related gastrointestinal disorders, availability of both otc and prescription symptom relief medications, expansion of gastroenterology care services.

The gastroparesis drugs market size is expected to see strong growth in the next few years. It will grow to $7.37 billion in 2030 at a compound annual growth rate (CAGR) of 5.2%. The growth in the forecast period can be attributed to rising global diabetes prevalence, growing awareness of gastroparesis as a chronic condition, increasing demand for effective long-term symptom control, expansion of access to specialty gastrointestinal care, ongoing need for improved motility-enhancing therapies. Major trends in the forecast period include growing reliance on prokinetic agents for symptom management, increasing use of combination drug therapy for gastroparesis, rising demand for prescription-based gastroparesis treatments, expansion of symptom-focused treatment approaches, greater use of oral drug formulations for long-term management.

The rising prevalence of diabetes is expected to drive the growth of the gastroparesis drugs market in the coming years. Diabetes is a long-term metabolic condition marked by high blood glucose levels caused by inadequate insulin production or ineffective insulin use. The incidence of diabetes is increasing due to factors such as sedentary lifestyles, unhealthy eating habits, genetic susceptibility, urbanization, aging populations, and rising obesity levels. The gastroparesis drugs market supports diabetes management by offering medications that help alleviate symptoms such as nausea, vomiting, and delayed gastric emptying, which are common gastrointestinal complications associated with diabetic gastroparesis. For example, in March 2024, according to the Office for Health Improvement & Disparities, a UK-based government department, between March 2022 and March 2023, the proportion of individuals with type 1 diabetes receiving all eight recommended care processes increased by 22%, while those with type 2 diabetes experienced a 21% increase. Additionally, the percentage of patients achieving target HbA1c levels rose to 37.9%, the highest figure ever recorded by the National Diabetes Audit. Therefore, the growing prevalence of diabetes is contributing to the expansion of the gastroparesis drugs market.

Major companies operating in the gastroparesis drugs market are concentrating on the development of innovative solutions, such as novel prokinetic therapies, to enhance gastric motility and reduce symptoms. Novel prokinetic therapies are newly developed medications intended to stimulate and improve the natural movement of the stomach and intestines, enabling food to pass more efficiently through the digestive system. For instance, in December 2023, Vanda Pharmaceuticals Inc., a US-based biopharmaceutical company, received acceptance from the U.S. Food and Drug Administration (FDA) for the filing of its New Drug Application (NDA) for tradipitant for the treatment of gastroparesis symptoms. Tradipitant is an investigational oral neurokinin-1 receptor antagonist aimed at addressing gastroparesis, a serious digestive condition with significant unmet medical needs. This acceptance represents an important regulatory milestone for Vanda as it continues efforts to obtain marketing approval for tradipitant in gastroparesis patients.

In May 2025, Renexxion Ireland Ltd., an Ireland-based biopharmaceutical company, entered into a partnership with Dr. Falk Pharma GmbH to support the global development of naronapride for the treatment of gastroparesis. The collaboration is intended to complete the global Phase 2b MOVE-IT study and accelerate the development of naronapride as a potential best-in-class therapy for gastroparesis. Dr. Falk Pharma GmbH is a Germany-based company specializing in digestive and metabolic medicine.

Major companies operating in the gastroparesis drugs market are Evoke Pharma Inc., Takeda Pharmaceutical Inc., AbbVie Inc., Salix Pharmaceuticals Inc., Pfizer Inc., Sanofi SA, AstraZeneca plc, Teva Pharmaceutical Inc., Bausch Health Companies Inc., Abbott Laboratories, GSK plc, Eisai Co. Ltd., Vanda Pharmaceuticals Inc., Theravance Biopharma Inc., ANI Pharmaceuticals Inc., Cadila Pharmaceuticals, Cipla Ltd., Ipca Laboratories Ltd., Neurogastrx Inc., Processa Pharmaceuticals Inc.

North America was the largest region in the gastroparesis drugs market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the gastroparesis drugs market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

The countries covered in the gastroparesis drugs market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The gastroparesis drugs market consists of sales of metoclopramide, ondansetron, amitriptyline, and erythromycin. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Gastroparesis Drugs Market Global Report 2026 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses gastroparesis drugs market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 16 geographies.
• Assess the impact of key macro factors such as geopolitical conflicts, trade policies and tariffs, inflation and interest rate fluctuations, and evolving regulatory landscapes.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on end user analysis.
• Benchmark performance against key competitors based on market share, innovation, and brand strength.
• Evaluate the total addressable market (TAM) and market attractiveness scoring to measure market potential.
• Suitable for supporting your internal and external presentations with reliable high-quality data and analysis
• Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for gastroparesis drugs ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The gastroparesis drugs market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, total addressable market (TAM), market attractiveness score (MAS), competitive landscape, market shares, company scoring matrix, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market. This section also examines key products and services offered in the market, evaluates brand-level differentiation, compares product features, and highlights major innovation and product development trends.
• The supply chain analysis section provides an overview of the entire value chain, including key raw materials, resources, and supplier analysis. It also provides a list competitor at each level of the supply chain.
• The updated trends and strategies section analyses the shape of the market as it evolves and highlights emerging technology trends such as digital transformation, automation, sustainability initiatives, and AI-driven innovation. It suggests how companies can leverage these advancements to strengthen their market position and achieve competitive differentiation.
• The regulatory and investment landscape section provides an overview of the key regulatory frameworks, regularity bodies, associations, and government policies influencing the market. It also examines major investment flows, incentives, and funding trends shaping industry growth and innovation.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include the technological advancements such as AI and automation, Russia-Ukraine war, trade tariffs (government-imposed import/export duties), elevated inflation and interest rates.
• The total addressable market (TAM) analysis section defines and estimates the market potential compares it with the current market size, and provides strategic insights and growth opportunities based on this evaluation.
• The market attractiveness scoring section evaluates the market based on a quantitative scoring framework that considers growth potential, competitive dynamics, strategic fit, and risk profile. It also provides interpretive insights and strategic implications for decision-makers.
• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth.
• Expanded geographical coverage includes Taiwan and Southeast Asia, reflecting recent supply chain realignments and manufacturing shifts in the region. This section analyzes how these markets are becoming increasingly important hubs in the global value chain.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The company scoring matrix section evaluates and ranks leading companies based on a multi-parameter framework that includes market share or revenues, product innovation, and brand recognition.

Scope

• Markets Covered:1) By Drug Type: Over-the-counter (OTC) Drugs; Prescription Drugs
• 2) By Drug Class: Prokinetic Agents; Antiemetic Drugs; Proton Pump Inhibitors; Other Drug Classes
• 3) By Disease Type: Diabetic Gastroparesis; Post-Surgical Gastroparesis; Idiopathic Gastroparesis; Other Disease Types
• 4) By Route Of Administration: Oral; Injectables; Other Routes Of Administration
• 5) By Distribution Channel: Hospitals; Pharmacies; Clinics; E-commerce
• Subsegments:
• 1) By Over-the-counter (OTC) Drugs: Antacids; Anti-Nausea Medications; Antiemetics; Digestive Enzyme Supplements
• 2) By Prescription Drugs: Prokinetic Agents; Antiemetic Drugs; Antibiotics; Antidepressants
• Companies Mentioned: Evoke Pharma Inc.; Takeda Pharmaceutical Inc.; AbbVie Inc.; Salix Pharmaceuticals Inc.; Pfizer Inc.; Sanofi SA; AstraZeneca plc; Teva Pharmaceutical Inc.; Bausch Health Companies Inc.; Abbott Laboratories; GSK plc; Eisai Co. Ltd.; Vanda Pharmaceuticals Inc.; Theravance Biopharma Inc.; ANI Pharmaceuticals Inc.; Cadila Pharmaceuticals; Cipla Ltd.; Ipca Laboratories Ltd.; Neurogastrx Inc.; Processa Pharmaceuticals Inc.
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Taiwan; Russia; South Korea; UK; USA; Canada; Italy; Spain.
• Regions: Asia-Pacific; South East Asia; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time Series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data Segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery Format: Word, PDF or Interactive Report
• + Excel Dashboard
• Added Benefits
• Bi-Annual Data Update
• Customisation
• Expert Consultant Support

Added Benefits available all on all list-price licence purchases, to be claimed at time of purchase. Customisations within report scope and limited to 20% of content and consultant support time limited to 8 hours.

Table of Contents

1. Executive Summary

• 1.1. Key Market Insights (2020-2035)
• 1.2. Visual Dashboard: Market Size, Growth Rate, Hotspots
• 1.3. Major Factors Driving the Market
• 1.4. Top Three Trends Shaping the Market

2. Gastroparesis Drugs Market Characteristics

• 2.1. Market Definition & Scope
• 2.2. Market Segmentations
• 2.3. Overview of Key Products and Services
• 2.4. Global Gastroparesis Drugs Market Attractiveness Scoring And Analysis
  • 2.4.1. Overview of Market Attractiveness Framework
  • 2.4.2. Quantitative Scoring Methodology
  • 2.4.3. Factor-Wise Evaluation
• Growth Potential Analysis, Competitive Dynamics Assessment, Strategic Fit Assessment And Risk Profile Evaluation
• 2.4.4. Market Attractiveness Scoring and Interpretation
• 2.4.5. Strategic Implications and Recommendations

3. Gastroparesis Drugs Market Supply Chain Analysis

• 3.1. Overview of the Supply Chain and Ecosystem
• 3.2. List Of Key Raw Materials, Resources & Suppliers
• 3.3. List Of Major Distributors and Channel Partners
• 3.4. List Of Major End Users

4. Global Gastroparesis Drugs Market Trends And Strategies

• 4.1. Key Technologies & Future Trends
  • 4.1.1 Biotechnology, Genomics & Precision Medicine
  • 4.1.2 Artificial Intelligence & Autonomous Intelligence
  • 4.1.3 Digitalization, Cloud, Big Data & Cybersecurity
  • 4.1.4 Industry 4.0 & Intelligent Manufacturing
  • 4.1.5 Sustainability, Climate Tech & Circular Economy
• 4.2. Major Trends
  • 4.2.1 Growing Reliance On Prokinetic Agents For Symptom Management
  • 4.2.2 Increasing Use Of Combination Drug Therapy For Gastroparesis
  • 4.2.3 Rising Demand For Prescription-Based Gastroparesis Treatments
  • 4.2.4 Expansion Of Symptom-Focused Treatment Approaches
  • 4.2.5 Greater Use Of Oral Drug Formulations For Long-Term Management

5. Gastroparesis Drugs Market Analysis Of End Use Industries

• 5.1 Hospitals
• 5.2 Clinics
• 5.3 Pharmacies
• 5.4 Specialty Gastroenterology Centers
• 5.5 Home Care Settings

6. Gastroparesis Drugs Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, Supply Chain Impact from Tariff War & Trade Protectionism, And Covid And Recovery On The Market

7. Global Gastroparesis Drugs Strategic Analysis Framework, Current Market Size, Market Comparisons And Growth Rate Analysis

• 7.1. Global Gastroparesis Drugs PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
• 7.2. Global Gastroparesis Drugs Market Size, Comparisons And Growth Rate Analysis
• 7.3. Global Gastroparesis Drugs Historic Market Size and Growth, 2020 - 2025, Value ($ Billion)
• 7.4. Global Gastroparesis Drugs Forecast Market Size and Growth, 2025 - 2030, 2035F, Value ($ Billion)

8. Global Gastroparesis Drugs Total Addressable Market (TAM) Analysis for the Market

• 8.1. Definition and Scope of Total Addressable Market (TAM)
• 8.2. Methodology and Assumptions
• 8.3. Global Total Addressable Market (TAM) Estimation
• 8.4. TAM vs. Current Market Size Analysis
• 8.5. Strategic Insights and Growth Opportunities from TAM Analysis

9. Gastroparesis Drugs Market Segmentation

• 9.1. Global Gastroparesis Drugs Market, Segmentation By Drug Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
• Over-the-counter (OTC) Drugs, Prescription Drugs
• 9.2. Global Gastroparesis Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
• Prokinetic Agents, Antiemetic Drugs, Proton Pump Inhibitors, Other Drug Classes
• 9.3. Global Gastroparesis Drugs Market, Segmentation By Disease Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
• Diabetic Gastroparesis, Post-Surgical Gastroparesis, Idiopathic Gastroparesis, Other Disease Types
• 9.4. Global Gastroparesis Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
• Oral, Injectables, Other Routes Of Administration
• 9.5. Global Gastroparesis Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
• Hospitals, Pharmacies, Clinics, E-commerce
• 9.6. Global Gastroparesis Drugs Market, Sub-Segmentation Of Over-the-counter (OTC) Drugs, By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
• Antacids, Anti-Nausea Medications, Antiemetics, Digestive Enzyme Supplements
• 9.7. Global Gastroparesis Drugs Market, Sub-Segmentation Of Prescription Drugs, By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
• Prokinetic Agents, Antiemetic Drugs, Antibiotics, Antidepressants

10. Gastroparesis Drugs Market Regional And Country Analysis

• 10.1. Global Gastroparesis Drugs Market, Split By Region, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
• 10.2. Global Gastroparesis Drugs Market, Split By Country, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

11. Asia-Pacific Gastroparesis Drugs Market

• 11.1. Asia-Pacific Gastroparesis Drugs Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 11.2. Asia-Pacific Gastroparesis Drugs Market, Segmentation By Drug Type, Segmentation By Drug Class, Segmentation By Disease Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

12. China Gastroparesis Drugs Market

• 12.1. China Gastroparesis Drugs Market Overview
• Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 12.2. China Gastroparesis Drugs Market, Segmentation By Drug Type, Segmentation By Drug Class, Segmentation By Disease Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

13. India Gastroparesis Drugs Market

• 13.1. India Gastroparesis Drugs Market, Segmentation By Drug Type, Segmentation By Drug Class, Segmentation By Disease Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

14. Japan Gastroparesis Drugs Market

• 14.1. Japan Gastroparesis Drugs Market Overview
• Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 14.2. Japan Gastroparesis Drugs Market, Segmentation By Drug Type, Segmentation By Drug Class, Segmentation By Disease Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

15. Australia Gastroparesis Drugs Market

• 15.1. Australia Gastroparesis Drugs Market, Segmentation By Drug Type, Segmentation By Drug Class, Segmentation By Disease Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

16. Indonesia Gastroparesis Drugs Market

• 16.1. Indonesia Gastroparesis Drugs Market, Segmentation By Drug Type, Segmentation By Drug Class, Segmentation By Disease Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

17. South Korea Gastroparesis Drugs Market

• 17.1. South Korea Gastroparesis Drugs Market Overview
• Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 17.2. South Korea Gastroparesis Drugs Market, Segmentation By Drug Type, Segmentation By Drug Class, Segmentation By Disease Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

18. Taiwan Gastroparesis Drugs Market

• 18.1. Taiwan Gastroparesis Drugs Market Overview
• Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 18.2. Taiwan Gastroparesis Drugs Market, Segmentation By Drug Type, Segmentation By Drug Class, Segmentation By Disease Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

19. South East Asia Gastroparesis Drugs Market

• 19.1. South East Asia Gastroparesis Drugs Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 19.2. South East Asia Gastroparesis Drugs Market, Segmentation By Drug Type, Segmentation By Drug Class, Segmentation By Disease Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

20. Western Europe Gastroparesis Drugs Market

• 20.1. Western Europe Gastroparesis Drugs Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 20.2. Western Europe Gastroparesis Drugs Market, Segmentation By Drug Type, Segmentation By Drug Class, Segmentation By Disease Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

21. UK Gastroparesis Drugs Market

• 21.1. UK Gastroparesis Drugs Market, Segmentation By Drug Type, Segmentation By Drug Class, Segmentation By Disease Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

22. Germany Gastroparesis Drugs Market

• 22.1. Germany Gastroparesis Drugs Market, Segmentation By Drug Type, Segmentation By Drug Class, Segmentation By Disease Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

23. France Gastroparesis Drugs Market

• 23.1. France Gastroparesis Drugs Market, Segmentation By Drug Type, Segmentation By Drug Class, Segmentation By Disease Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

24. Italy Gastroparesis Drugs Market

• 24.1. Italy Gastroparesis Drugs Market, Segmentation By Drug Type, Segmentation By Drug Class, Segmentation By Disease Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

25. Spain Gastroparesis Drugs Market

• 25.1. Spain Gastroparesis Drugs Market, Segmentation By Drug Type, Segmentation By Drug Class, Segmentation By Disease Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

26. Eastern Europe Gastroparesis Drugs Market

• 26.1. Eastern Europe Gastroparesis Drugs Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 26.2. Eastern Europe Gastroparesis Drugs Market, Segmentation By Drug Type, Segmentation By Drug Class, Segmentation By Disease Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

27. Russia Gastroparesis Drugs Market

• 27.1. Russia Gastroparesis Drugs Market, Segmentation By Drug Type, Segmentation By Drug Class, Segmentation By Disease Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

28. North America Gastroparesis Drugs Market

• 28.1. North America Gastroparesis Drugs Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 28.2. North America Gastroparesis Drugs Market, Segmentation By Drug Type, Segmentation By Drug Class, Segmentation By Disease Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

29. USA Gastroparesis Drugs Market

• 29.1. USA Gastroparesis Drugs Market Overview
• Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 29.2. USA Gastroparesis Drugs Market, Segmentation By Drug Type, Segmentation By Drug Class, Segmentation By Disease Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

30. Canada Gastroparesis Drugs Market

• 30.1. Canada Gastroparesis Drugs Market Overview
• Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 30.2. Canada Gastroparesis Drugs Market, Segmentation By Drug Type, Segmentation By Drug Class, Segmentation By Disease Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

31. South America Gastroparesis Drugs Market

• 31.1. South America Gastroparesis Drugs Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 31.2. South America Gastroparesis Drugs Market, Segmentation By Drug Type, Segmentation By Drug Class, Segmentation By Disease Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

32. Brazil Gastroparesis Drugs Market

• 32.1. Brazil Gastroparesis Drugs Market, Segmentation By Drug Type, Segmentation By Drug Class, Segmentation By Disease Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

33. Middle East Gastroparesis Drugs Market

• 33.1. Middle East Gastroparesis Drugs Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 33.2. Middle East Gastroparesis Drugs Market, Segmentation By Drug Type, Segmentation By Drug Class, Segmentation By Disease Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

34. Africa Gastroparesis Drugs Market

• 34.1. Africa Gastroparesis Drugs Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 34.2. Africa Gastroparesis Drugs Market, Segmentation By Drug Type, Segmentation By Drug Class, Segmentation By Disease Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

35. Gastroparesis Drugs Market Regulatory and Investment Landscape

36. Gastroparesis Drugs Market Competitive Landscape And Company Profiles

• 36.1. Gastroparesis Drugs Market Competitive Landscape And Market Share 2024
  • 36.1.1. Top 10 Companies (Ranked by revenue/share)
• 36.2. Gastroparesis Drugs Market - Company Scoring Matrix
  • 36.2.1. Market Revenues
  • 36.2.2. Product Innovation Score
  • 36.2.3. Brand Recognition
• 36.3. Gastroparesis Drugs Market Company Profiles
  • 36.3.1. Evoke Pharma Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 36.3.2. Takeda Pharmaceutical Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 36.3.3. AbbVie Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 36.3.4. Salix Pharmaceuticals Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 36.3.5. Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis

37. Gastroparesis Drugs Market Other Major And Innovative Companies

• Sanofi SA, AstraZeneca plc, Teva Pharmaceutical Inc., Bausch Health Companies Inc., Abbott Laboratories, GSK plc, Eisai Co. Ltd., Vanda Pharmaceuticals Inc., Theravance Biopharma Inc., ANI Pharmaceuticals Inc., Cadila Pharmaceuticals, Cipla Ltd., Ipca Laboratories Ltd., Neurogastrx Inc., Processa Pharmaceuticals Inc.

38. Global Gastroparesis Drugs Market Competitive Benchmarking And Dashboard

39. Key Mergers And Acquisitions In The Gastroparesis Drugs Market

40. Gastroparesis Drugs Market High Potential Countries, Segments and Strategies

• 40.1 Gastroparesis Drugs Market In 2030 - Countries Offering Most New Opportunities
• 40.2 Gastroparesis Drugs Market In 2030 - Segments Offering Most New Opportunities
• 40.3 Gastroparesis Drugs Market In 2030 - Growth Strategies
  • 40.3.1 Market Trend Based Strategies
  • 40.3.2 Competitor Strategies

41. Appendix

• 41.1. Abbreviations
• 41.2. Currencies
• 41.3. Historic And Forecast Inflation Rates
• 41.4. Research Inquiries
• 41.5. The Business Research Company
• 41.6. Copyright And Disclaimer